Researchers discovered that a specific protein called GAP-43 plays a crucial role in protecting brain cells from damage caused by α-synuclein, a protein involved in Parkinson’s Disease. When GAP-43 is modified through a process called phosphorylation at certain sites, it promotes the growth of neurites (neural connections) and formation of healthy synapses. The drug FK506, already approved by the FDA, appears to work by controlling this phosphorylation process, offering potential therapeutic benefits for Parkinson’s patients.